Company news

Percheron Therapeutics Limited news in 2024

Percheron Therapeutics Limited's news releases, calls and decks from 2024, newest first.

View company

Topline Six-Month Results From Phase IIb Study of Avicursen

December 17, 2024

Clinical Trial Update

December 1, 2024

Results of Share Purchase Plan

November 12, 2024

Percheron to launch Share Purchase Plan

October 22, 2024

$13.0 million Institutional Placement

October 17, 2024

Completion of avicursen (ATL1102) toxicology study

September 29, 2024

Phase IIb study of ATL1102 in DMD completes recruitment

May 28, 2024

Receipt of R&D Tax incentive payment

February 11, 2024

Decks in 2024